Is a self-report RAPID3 score a reasonable alternative to a DAS28 in usual clinical care?

Journal of Clinical Rheumatology

Volumn 15, Issue 5, 2009, Pages 215-217

  Pincus, Theodore ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; RHEUMATOID FACTOR;

CLINICAL ASSESSMENT; DISEASE ACTIVITY SCORE; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE; HUMAN; JOINT EXAMINATION; LABORATORY TEST; MEDICAL PRACTICE; MEDICAL RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SCORING SYSTEM; SELF REPORT;

ARTHRITIS, RHEUMATOID; HUMANS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 69649104338     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181b40a9a     Document Type: Editorial

References (35)

1. Lindsay K, Ibrahim G, Sokoll K, et al. The composite DAS score is impractical to use in daily practice - evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol. 2009;15:223-225.
2. van der Heijde DMFM, van't Hof MA, van Riel PLCM, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916-920.
3. van der Heijde DMFM, van't Hof M, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20:579-581.
4. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. J Rheumatol. 1993;20:575-578.
5. Colglazier CL, Swearingen C, Kaell A, et al. Time to score indices to assess clinical status in RA: Disease Activity Score (DAS28), Clinical Disease Activity Index (CDAI), Easy Rheumatoid Arthritis Measure (ERAM) and Routine Assessment of Patient Index Data (RAPID3) in usual clinical care. Arthritis Rheum. 2008;58(suppl):S750-S751. Ref Type: Abstract.
6. Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-joint count, disease activity score, health assessment questionnaire (HAQ), multidimensional HAQ (MDHAQ), and routine assessment of patient index data (RAPID) scores. J Rheumatol. 2008;35:603-609.
7. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol. 1994;21:1227-1237. (Pubitemid 24234657)
8. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. J Rheumatol. 2009;In press.
9. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. (Pubitemid 351650500)
10. Hakkinen A, Kautiainen H, Hannonen P, et al. Muscle strength, pain, and disease activity explain individual subdimensions of the health assessment questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis. 2006;65(1):30-34. (Pubitemid 41819020)
11. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100-S108. (Pubitemid 46657517)
12. Pincus T, Amara I, Segurado OG, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35(2):201-205. (Pubitemid 351284437)
13. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis. 2006;65:820-822. (Pubitemid 43799185)
14. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008;66(3):216-223.
15. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum. 2002;46(4):851-854. (Pubitemid 34303793)
16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
17. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum. 1999;42:2220-2230. (Pubitemid 30263609)
18. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol. 2005;32:1432-1439. (Pubitemid 41113961)
19. Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis. 2007;65(2):150-160. (Pubitemid 350291162)
20. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol. 2008;35:2136-2147.
21. Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008;47(3):345-349. (Pubitemid 351267204)
22. Pincus T, Amara I, Segurado O, Koch G. An index based on only patient reported outcome (PRO) measures, routine assessment of patient index data (RAPID3), distinguishes adalimumab from control at levels similar to disease activity score (DAS28) and clinical disease activity index (CDAI). Ann Rheum Dis. 2007;66:184. Ref Type: Abstract.
23. Pincus T, Chung C, Segurado OG, et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006;33:2146-2152. (Pubitemid 44749771)
24. Pincus T, Keystone E, Fischer A, et al. Patients in the RAPID1 (rheumatoid arthritis prevention of structural damage) clinical trial of certolizumab pegol (CZP) have similar high/moderate vs low activity/remission status according to 3 indices, DAS28 (disease activity score), CDAI (clinical disease activity index) and RAPID3 (routine assessment of patient index data), and similar EULAR-DAS and proposed RAPID3 good, moderate and poor responses. Ann Rheum Dis in press. 2009. Ref Type: Abstract.
25. Pincus T, Callahan LF, Vaughn WK, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-872. (Pubitemid 14067781)
26. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5[Suppl. 51]):S35-S61.
27. Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol. 2007;21(4):601-628. (Pubitemid 47189089)
28. Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: Improving efficiency and documenting care. J Rheumatol. 2000;27:2727-12230
29. Pincus T, Yazici Y, Bergman M. Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol. 2005;23:S19-S28. (Pubitemid 46661464)
30. Wolfe F, Michaud K, Pincus T, et al. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005;52(12):3873-3879. (Pubitemid 41798226)
31. Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol. 2006;33:834-837.
32. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol. 2005;32:575-577. (Pubitemid 40524685)
33. Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? Best Pract Res Clin Rheumatol. 2007;21(4):733-753. (Pubitemid 47189088)
34. Pincus T, Yazici Y, Bergman MJ. Hotel-based medicine. J Rheumatol. 2008;35(8):1487-1488.
35. Pincus T, Tugwell P. Shouldn't standard rheumatology clinical care be "evidence-based" rather than "eminence-based," "eloquence-based" or "elegance-based"? J Rheumatol. 2007;34:1-4 (Pubitemid 46106553)